

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Toshihiro TANAKA et al.

Group Art Unit : 1634

Appln. No. : 10/568,695

I.A. Filed : August 18, 2004

Examiner : Stephen Thomas Kapushoc

For : METHOD OF JUDGING INFLAMMATORY DISEASE BY USING SINGLE
NUCLEOTIDE POLYMORPHISM IN GALECTIN-2 GENE

DECLARATION UNDER 37 C.F.R. § 1.132

Commissioner for Patents
U.S. Patent and Trademark Office
Customer Service Window, Mail Stop AMENDMENT
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Sir :

I, the undersigned, Kouichi Ozaki, declare:

That I am a citizen of Japan, and my resides is Suehiro-cho 1-7-22, Tsurumi-ku,
Yokohama, Kanagawa, 230-0045 Japan.

That my education and employment history is as follows:

Education:

1985-1989 Tohoku Pharmaceutical University

1989-1991 Graduate School of Tohoku Pharmaceutical University

Degree:

M.Sc. (Tohoku Pharmaceutical University; March 1991)

Ph. D. (Medicine, Osaka University; March 1999)

Qualifications:

Pharmacist (May 1991)

Career

2008- Present

Senior Research Scientist, Laboratory for Cardiovascular Disease, Center for Genomic Medicine, RIKEN

2005-2008

Senior Research Scientist, Laboratory for Cardiovascular Disease, SNP Research Center, RIKEN

2000-2005

Research Scientist, Laboratory for Cardiovascular Disease, SNP Research Center, RIKEN

1997-2000

Laboratory Sub-Head, Laboratory for Structural Genomics, Otsuka GEN Research institute, Otsuka Pharmaceutical Co. Ltd.

1993-1997

Research Scientist, Laboratory for Structural Genomics, Otsuka GEN Research institute, Otsuka Pharmaceutical Co. Ltd.

1991-1993

Research Scientist, Laboratory for Diagnosis, Otsuka Pharmaceutical Co. Ltd.

I declare further that the following statements are true and correct to the best of my knowledge.

Asselbergs et al (Clinical Science (2007) 112, 291-298) discloses an association in a non-Japanese population between the SNP at 3279 and myocardial infarction. Namely, in "study population" of "METHODS" of Asselbergs et al (page 292), it is described that myocardial infarction is used as an ischemic cardiac disease. Also, in Table 1 of Asselbergs et al (page 293), family history of myocardial infarction (MI) is described. In "METHODS" section, non-fatal- myocardial infarction (MI) or fatal CHD is recited. This shows that this study uses samples of patients who suffered MI but did not die and

patients who did not diagnosed conclusively to be MI but suffered fetal CHD. Severe CHD is considered to be converted to MI if it is not treated immediately. Therefore, severe CAD can be explained in the same way as in the case of MI. Therefore, Asselbergs et al (Clinical Science (2007) 112, 291-298) discloses an association in a non-Japanese population between the SNP at 3279 and myocardial infarction.

I, further declare that all statements made herein of our own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements were made with knowledge that willful false statements and the like so made are punishable by fine or imprisonment or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the above-captioned application or any patent issuing therefrom.

May 21, 2010
Date

Kouichi Ozaki
Kouichi Ozaki